发布求助
文献互助 智能选刊 最新文献

Clinical Liver Disease最新文献

筛选
英文 中文
Epidemiology, natural history, and management of patients with CHB concurrent with MASLD. CHB并发MASLD患者的流行病学、自然病史和管理。
Clinical Liver Disease Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000171
Wenjing Ni, Junping Shi, Jie Li
{"title":"Epidemiology, natural history, and management of patients with CHB concurrent with MASLD.","authors":"Wenjing Ni, Junping Shi, Jie Li","doi":"10.1097/CLD.0000000000000171","DOIUrl":"10.1097/CLD.0000000000000171","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0171"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of chronic hepatitis B infection in children. 儿童慢性乙型肝炎感染的管理。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000156
Huey-Ling Chen
{"title":"Management of chronic hepatitis B infection in children.","authors":"Huey-Ling Chen","doi":"10.1097/CLD.0000000000000156","DOIUrl":"10.1097/CLD.0000000000000156","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0156"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with CHB outside the guidelines: Insights from Egyptian cohort with long-term follow-up. 指南之外的慢性阻塞性肺病患者管理：埃及队列长期随访的启示。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000183
Gamal Shiha, Riham Soliman, Ayman Hassan, Ahmed Farahat, Ahmed Salem, Amr Taha, Ramy Sabry, Ahmed Geith, Ahmed Elshawaf, Nabiel Mikhail
{"title":"Management of patients with CHB outside the guidelines: Insights from Egyptian cohort with long-term follow-up.","authors":"Gamal Shiha, Riham Soliman, Ayman Hassan, Ahmed Farahat, Ahmed Salem, Amr Taha, Ramy Sabry, Ahmed Geith, Ahmed Elshawaf, Nabiel Mikhail","doi":"10.1097/CLD.0000000000000183","DOIUrl":"10.1097/CLD.0000000000000183","url":null,"abstract":"<p><p>It is alarming that globally, only 2.2% (6.6 million) of patients with chronic hepatitis B (CHB) received treatment in 2019. One contributing factor to this low treatment rate is the complexity and restrictive nature of clinical practice guidelines. Since 1998, we have adopted a \"treat-all\" approach to patients with CHB. A retrospective study was conducted involving patients with CHB who received treatment from 1998 to 2020 at 2 institutions in Egypt. These patients underwent evaluation through various clinical and laboratory methods, which included testing for liver enzymes and HBV DNA. The study analyzed 1825 patients with HBV, finding that 27.4% had viremia levels under 2000 IU/mL. Most (88%) were HBeAg-negative, with 12% positive. A large portion (77.6%) had normal alanine aminotransferase levels, though 5.6% exceeded twice the upper limit of normal. About 14.2% were diagnosed with liver cirrhosis, and 9.6% with F3 stage fibrosis at enrollment. Notably, 2% (25 cases) lost HBsAg over a median of 52 months. Patients with HBV DNA <2000 IU/mL had a higher HBsAg loss rate (4.2%) compared to those with levels >2000 IU/mL (1.3%). During follow-up, 9.5% (117 patients) experienced decompensation, with a higher incidence in those with HBV DNA <2000 IU/mL (16.8%) than those >2000 IU/mL (7.1%). HCC developed in 5.2% of patients with lower HBV DNA and 2.6% with higher levels, showing significant differences. Liver-related deaths occurred in 2.8% of the cohort, with a slightly higher rate in those with lower initial HBV DNA levels (3.5% vs. 2.5%). The findings suggest a paradigm shift in CHB management toward early and broader eligibility for antiviral therapy. This could improve patient outcomes and address the global treatment gap in CHB management, especially in regions with high CHB prevalence.</p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0183"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A severe case of hypercalcemia in a patient with presumed cryptogenic cirrhosis. 一例推测为隐源性肝硬化患者的严重高钙血症病例。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000230
Agnieszka Maniak, Nancy Reau
{"title":"A severe case of hypercalcemia in a patient with presumed cryptogenic cirrhosis.","authors":"Agnieszka Maniak, Nancy Reau","doi":"10.1097/CLD.0000000000000230","DOIUrl":"10.1097/CLD.0000000000000230","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0230"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noncirrhotic portal hypertension-Historical perspectives bring clarity to the entity and its management. 非肝硬化性门脉高压症--历史的视角让这一疾病及其治疗更加清晰。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000232
Cyriac Abby Philips, Shiv K Sarin
{"title":"Noncirrhotic portal hypertension-Historical perspectives bring clarity to the entity and its management.","authors":"Cyriac Abby Philips, Shiv K Sarin","doi":"10.1097/CLD.0000000000000232","DOIUrl":"10.1097/CLD.0000000000000232","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0232"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of patient-reported outcomes in a patient-centered care model for managing chronic liver diseases. 患者报告结果在以患者为中心的慢性肝病管理模式中的作用。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000222
Manisha Verma, Archita P Desai
{"title":"The role of patient-reported outcomes in a patient-centered care model for managing chronic liver diseases.","authors":"Manisha Verma, Archita P Desai","doi":"10.1097/CLD.0000000000000222","DOIUrl":"10.1097/CLD.0000000000000222","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0222"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of immune therapy in HCC: Where are we now and what is the future? 回顾 HCC 的免疫疗法：现状与未来？
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000149
Valentina Zanuso, Angelo Pirozzi, Giulia Tesini, Lorenza Rimassa
{"title":"Review of immune therapy in HCC: Where are we now and what is the future?","authors":"Valentina Zanuso, Angelo Pirozzi, Giulia Tesini, Lorenza Rimassa","doi":"10.1097/CLD.0000000000000149","DOIUrl":"10.1097/CLD.0000000000000149","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0149"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond. 炎症性肠病的肝毒性：免疫调节剂、生物制剂及其他。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000199
Helgi K Björnsson, Einar S Björnsson
{"title":"Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond.","authors":"Helgi K Björnsson, Einar S Björnsson","doi":"10.1097/CLD.0000000000000199","DOIUrl":"10.1097/CLD.0000000000000199","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0199"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
(P)rehabilitation in advanced chronic liver disease (advCLD): From basic exercise concepts to implementation challenges. (晚期慢性肝病（advCLD）的（康复）治疗：从基本运动概念到实施挑战。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000184
Andrew P Kassa, Jonathan G Stine
{"title":"(P)rehabilitation in advanced chronic liver disease (advCLD): From basic exercise concepts to implementation challenges.","authors":"Andrew P Kassa, Jonathan G Stine","doi":"10.1097/CLD.0000000000000184","DOIUrl":"10.1097/CLD.0000000000000184","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0184"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethics in hepatology: A professional and very personal journey. 肝病学的伦理：专业和个人的旅程。
Clinical Liver Disease Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000231
Dirk J van Leeuwen
{"title":"Ethics in hepatology: A professional and very personal journey.","authors":"Dirk J van Leeuwen","doi":"10.1097/CLD.0000000000000231","DOIUrl":"10.1097/CLD.0000000000000231","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":"23 1","pages":"e0231"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信